TCIM is a transcriptional regulator with pleiotropic roles in cell growth, differentiation, and immune signaling that vary substantially by tissue context. In normal physiology, TCIM enhances the WNT–CTNNB1 pathway by antagonizing CBY1, promotes follicular dendritic cell proliferation, and positively regulates G1-to-S-phase cell cycle transition through MAPK2/3 signaling. In endothelial cells, it amplifies inflammatory mediators by modulating NF-κB activity and participates in heat-shock response via feedback with HSF1. However, its roles in cancer are contradictory: in thyroid and lung cancers, TCIM overexpression promotes proliferation and blocks apoptosis 1, whereas in hepatocellular carcinoma, it suppresses self-renewal by antagonizing NOTCH2 signaling. A recent transcriptomic study identified TCIM expression as part of a brain gene signature correlated with adherence to the MIND diet and associated with slower cognitive decline and lower dementia odds 2, suggesting a neuroprotective role. The gene's tissue-dependent and sometimes opposing functions underscore the complexity of its regulatory networks and indicate that its clinical relevance depends critically on cancer type and cellular context.